The immune monitoring solutions market is projected to grow at a CAGR of 13.00%, driven by rising demand for advanced immunology diagnostics and personalized medicine. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immune Monitoring Solutions Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immune Monitoring Solutions Market, by Method
8.1.1 Flow Cytometry
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunohistochemistry
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Immune Monitoring Solutions Market, by Application
9.1.1. Vaccine Development
9.1.1.1. Market Revenue and Forecast
9.1.2. Transplantation Research
9.1.2.1. Market Revenue and Forecast
9.1.3. Precision Medicine & Immunotherapy Trials
9.1.3.1. Market Revenue and Forecast
9.1.4. Allergy Research
9.1.4.1. Market Revenue and Forecast
9.1.5. Metabolism Studies
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Immune Monitoring Solutions Market, by End-Use
10.1.1. Pharmaceutical and Biopharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Government & Academic Research Labs & Institutes
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Method
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by End-Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Method
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by End-Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Method
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by End-Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Method
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by End-Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Method
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by End-Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Method
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by End-Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Method
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by End-Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Method
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by End-Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Method
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by End-Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Method
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by End-Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Method
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by End-Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Method
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by End-Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Method
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by End-Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Method
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by End-Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Method
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by End-Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Method
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by End-Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Method
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by End-Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Method
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by End-Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Method
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by End-Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Method
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by End-Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Method
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by End-Use
12.1. Becton Dickinson
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Creative Biolabs
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Precision Medicine Group, LLC.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Beckman Coulter, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Q2 Solutions and (Rules-Based Medicine)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Medigene AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ImmuMap Services ApS
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample